These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22229405)

  • 1. MDV3100 for the treatment of prostate cancer.
    Mukherji D; Pezaro CJ; De-Bono JS
    Expert Opin Investig Drugs; 2012 Feb; 21(2):227-33. PubMed ID: 22229405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
    Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
    Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
    Bennett LL; Ingason A
    Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of metastatic castration-resistant prostate cancer following docetaxel].
    Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical guide to the use of enzalutamide.
    Hoffman-Censits J; Kelly WK
    Can J Urol; 2014 Apr; 21(2 Supp 1):64-9. PubMed ID: 24775726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.
    Menon MP; Higano CS
    Curr Oncol Rep; 2013 Apr; 15(2):69-75. PubMed ID: 23341368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
    World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
    Kim W; Ryan CJ
    Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Scher HI; Beer TM; Higano CS; Anand A; Taplin ME; Efstathiou E; Rathkopf D; Shelkey J; Yu EY; Alumkal J; Hung D; Hirmand M; Seely L; Morris MJ; Danila DC; Humm J; Larson S; Fleisher M; Sawyers CL;
    Lancet; 2010 Apr; 375(9724):1437-46. PubMed ID: 20398925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased survival with enzalutamide in prostate cancer after chemotherapy.
    Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
    N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
    Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
    Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
    Pal SK; Twardowski P; Josephson DY
    Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.